TNFRSF8 and Hodgkins lymphoma: It is also possible to consider A+AVD (brentuximab bedotin, doxorubicin, vinblastine, dacarbazine) regimen omitting bleomycin and introducing adcetris (anti CD30—brentuximab vedotin) based on the results of ECHELON-1 study which demonstrated that brentuximab vedotin (A) with AVD exhibited superior modified PFS vs. ABVD for frontline treatment for patients with stage III/IV classical HL (46), and because of the approval in Lebanon of A + AVD for first line therapy for stage IV HL.